Synopsis: Epigral reported a strong Q1 FY27 with revenue rising 15 percent and net profit growing 25 percent YoY, supported by higher sales volumes and better realizations. The company also unveiled new specialty chemicals projects while continuing multiple expansion initiatives that are expected to drive long-term growth.
Shares of Epigral Limited are likely to remain in focus after the company reported healthy growth in its Q1 FY27 earnings, driven by higher sales volumes, improved product realizations and resilient demand despite global macroeconomic volatility. Alongside its quarterly performance, the company announced fresh investments in specialty chemicals and continued execution of multiple capacity expansion projects aimed at strengthening its integrated manufacturing platform.
Epigral Limited has a total market capitalization of approximately Rs. 5,025.97 crore. The company’s shares were trading at Rs. 1165 apiece on the stock exchange. The stock has gained 7.55 percent over the last five trading sessions and gained 5.33 percent over the past month. It touched a 52-week high of Rs. 2114 and a 52-week low of Rs. 807.
Q1 FY27 Financial Performance
Epigral reported revenue of Rs. 709 crore during Q1 FY27, registering a 15 percent year-on-year growth from Rs. 615 crore in the corresponding quarter last year. The growth was supported by a 5 percent increase in sales volumes, improved product realizations and plant utilization of over 80 percent, indicating healthy demand across its product portfolio.
The company’s profitability also improved. EBITDA increased 10 percent to Rs. 179 crore compared to Rs. 163 crore a year ago, while the EBITDA margin stood at 25 percent. Profit before tax rose 25 percent to Rs. 133 crore, and net profit climbed 25 percent to Rs. 99 crore from an adjusted Rs. 79 crore in Q1 FY26. Earnings per share improved to Rs. 23 from Rs. 18.4 in the previous year.
Despite geopolitical tensions in West Asia that caused fluctuations in raw material prices, freight costs and shipment delays, Epigral managed to deliver double-digit growth by leveraging its diversified product portfolio and integrated manufacturing operations. Higher volumes and better product pricing helped offset these external challenges, allowing the company to maintain healthy profitability.
Another positive indicator was the company’s financial position. Net debt remained comfortable with a Net Debt-to-EBITDA ratio of 0.8x, providing sufficient flexibility to fund ongoing expansion projects without significantly stretching the balance sheet.
Major expansion plans to drive future growth
Epigral continued strengthening its long-term growth pipeline through multiple expansion projects across specialty chemicals. The Board approved the setting up of an Epoxy Resin & Formulations plant with an annual capacity of 1,25,000 tonnes at its Dahej manufacturing complex. The project is expected to be commissioned in H2 FY28 and will cater to fast-growing industries such as renewable energy, construction, electronics, automotive, infrastructure, marine and aerospace. The plant will also consume Epichlorohydrin and Caustic Soda produced internally, improving integration and margins.
The company also approved a new Multi-Purpose Plant (MPP) that will manufacture downstream products using Epichlorohydrin and Chlorotoluenes as feedstock. The facility will focus on import-substitute specialty chemicals catering to pharmaceutical intermediates, agrochemicals and water treatment chemicals, further expanding Epigral’s specialty chemicals portfolio. Both projects are scheduled for commissioning in H2 FY28. Apart from the newly announced projects, Epigral is nearing completion of several large capacity additions that are expected to start contributing from Q2 FY27.
The company is expanding its CPVC Resin capacity by 75,000 tonnes per annum, taking the total installed capacity to 1,50,000 tonnes, making it the world’s largest CPVC resin manufacturing facility by capacity. Demand for CPVC in India is expected to grow at around 12–13 percent CAGR, supported by rising demand from plumbing and infrastructure sectors.
Similarly, Epigral is doubling its Epichlorohydrin (ECH) capacity by adding 50,000 tonnes, increasing the total capacity to 1,00,000 tonnes, making it India’s largest ECH manufacturing plant. The company expects strong double-digit demand growth for ECH, which is widely used in epoxy resins and specialty chemical applications.
Additionally, the company is commissioning an additional 19.8 MW Wind-Solar Hybrid Power Plant, which is expected to lower energy costs while supporting sustainability initiatives.
Management believes operating conditions have stabilized despite global uncertainties and remains confident about India’s long-term economic growth. The company expects its integrated manufacturing model to continue supporting margin expansion while reducing dependence on imported raw materials.
The upcoming specialty chemical projects are expected to diversify revenue streams and strengthen Epigral’s position in higher-margin businesses. By consuming more of its own intermediate chemicals internally, the company also aims to improve operational efficiency and reduce raw material costs over time.
Incorporated in 2007, Epigral Limited (formerly Meghmani Finechem Limited) is one of India’s leading integrated chemical manufacturers. The company produces chlor-alkali products, derivatives and specialty chemicals through its fully integrated manufacturing complex at Dahej, Gujarat. Its product portfolio includes caustic soda, caustic potash, chloromethanes, hydrogen peroxide, CPVC resin, epichlorohydrin and chlorotoluenes, serving industries such as infrastructure, pharmaceuticals, agrochemicals, textiles, water treatment, renewable energy and automotive. The company continues to expand its specialty chemicals business through large-scale capacity additions and downstream integration initiatives.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses arising from decisions based on this article. Please consult your investment advisor before investing.
